AKRO - AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics Inc. (NASDAQ: AKRO) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action | Benzinga

NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of investors in Akero Therapeutics, Inc. (NASDAQ:AKRO) between September 13, 2022, and October 9, 2023, inclusive (the "Class Period").

Investors who purchased Akero stock may move the U.S. District Court for the Northern District of California to appoint them as lead plaintiff, no later than June 25, 2024. Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at elechtzin@edelson-law.com. A copy of the class action complaint can be viewed HERE.

Background on Akero Therapeutics, Inc.

Akero Therapeutics, Inc. is a clinical-stage company developing treatments for serious metabolic diseases with high unmet medical needs. Akero's lead product candidate, EFX, is a protein that was engineered to mimic the effect of fibroblast growth factor 21 ("FGF21"), a naturally occurring human hormone that protects against cellular stress and regulates whole-body metabolism and tissue-specific stress responses.

Over the past several years, Akero has designed and overseen a series of clinical trials to test the efficacy and safety of EFX in treating nonalcoholic steatohepatitis ("NASH"), a serious form of nonalcoholic fatty liver disease ("NAFLD") that is estimated to affect 17 million Americans. The most reliable diagnosis and staging of NASH is achieved by examining a liver biopsy specimen ...

AKRO) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action>Full story available on Benzinga.com